Voyager Therapeutics, Inc. (VYGR)

Market Cap	174.45M
Revenue (ttm)	80.00M
Net Income (ttm)	-65.00M
Shares Out	55.21M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	338,684
Open	3.090
Previous Close	3.130
Day's Range	3.070 - 3.175
52-Week Range	2.750 - 9.550
Beta	1.02
Analysts	Strong Buy
Price Target	14.86 (+371.0%)
Earnings Date	May 12, 2025

About VYGR

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company’s lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer’s disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 172
• Stock Exchange: NASDAQ
• Ticker Symbol: VYGR
• Website: https://www.voyagertherapeutics.com

Analyst Forecast

According to 9 analysts, the average rating for VYGR stock is "Strong Buy." The 12-month stock price forecast is $14.86, which is an increase of 371.00% from the latest price.

Price Target

$14.86

(371.00% upside)

Analyst Consensus: Strong Buy